This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
antibody
product name :
RABBIT ANTI UBC13 (C-TERMINAL)
catalog :
AHP974
quantity :
0.1 mg
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human, mouse
application :
western blot
citations: 2
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
product information
Entity Category :
Antibodies
Region :
(C-TERMINAL)
Product Code :
AHP974
Description :
RABBIT ANTI UBC13 (C-TERMINAL)
Specificity :
UBC13
Target Species :
Human
Host :
Rabbit
Format :
Purified
Isotypes :
Polyclonal IgG
Applications :
P*, WB
Application Types :
Western Blotting, Immunohistology - Paraffin
Cross Reactivities :
Mouse, Rat
Quantity :
0.1 mg
Quantity Value :
0.1 mg
Quantity Type :
mg
GO Accessions :
GO:0000724, GO:0000729, GO:0002755, GO:0005829, GO:0004842, GO:0005524, GO:0005634, GO:0006301, GO:0006508, GO:0008063, GO:0016574, GO:0031058, GO:0031372, GO:0033182, GO:0034130, GO:0034134, GO:0034142, GO:0043123, GO:0043130, GO:0043687, GO:0045087, GO:0045739, GO:0050852, GO:0051092, GO:0051443, GO:0070534
GO Terms :
activation of DNA repair, activation of histone modification, activation of I-kappaB kinase/NF-kappaB cascade, activation of NF-kappaB, activation of NF-kappaB transcription factor, activation of ubiquitin ligase activity, anaphase promoting complex activator, anaphase-promoting complex activator, anaphase-promoting complex activity, APC activation, APC activator, ATP-dependent proteolysis, cell nucleus, E2, E3, GO:0002226, GO:0004840, GO:0004841, GO:0016924, HDR, histone ubiquitinylation, histone ubiquitylation, homologous recombinational repair, homology-directed repair, HRR, MyD88-dependent TLR signaling pathway, MyD88-dependent toll-like receptor signalling pathway, NF-kappaB activation, nonspecific immune response, peptidolysis, positive regulation of ubiquitin ligase activity, postreplication DNA repair, posttranslational amino acid modification, post-translational amino acid modification, posttranslational modification, post-translational modification, posttranslational protein modification, PTM, Rad51-dependent recombinational repair, Rhp51-dependent recombinational repair, SCF complex activator, stimulation of DNA repair, stimulation of histone modification, stimulation of I-kappaB kinase/NF-kappaB cascade, stimulation of ubiquitin ligase activity, T lymphocyte receptor signaling pathway, T lymphocyte receptor signalling pathway, T-cell receptor signaling pathway, T-cell receptor signalling pathway, TCR signaling pathway, Tl signaling pathway, Tl signalling pathway, TLR1 signaling pathway, TLR2 signaling pathway, TLR4 signaling pathway, T-lymphocyte receptor signaling pathway, T-lymphocyte receptor signalling pathway, Toll signalling pathway, toll-like receptor 1 signalling pathway, toll-like receptor 2 signalling pathway, toll-like receptor 4 signalling pathway, ubiquitin activity, ubiquitin conjugating enzyme activity, ubiquitin ligase activator, ubiquitin ligase activity, ubiquitin protein ligase activity, ubiquitin protein-ligase activity, ubiquitin:protein-lysine N-ligase (AMP-forming) activity, ubiquitin-conjugating enzyme activity, ubiquitin-ligase activity, up regulation of DNA repair, up regulation of histone modification, up regulation of I-kappaB kinase/NF-kappaB cascade, up regulation of ubiquitin ligase activity, upregulation of DNA repair, up-regulation of DNA repair, upregulation of histone modification, up-regulation of histone modification, up-regulation of I-kappaB kinase/NF-kappaB cascade, upregulation of I-kappaB kinase/NF-kappaB cascade, upregulation of ubiquitin ligase activity, up-regulation of ubiquitin ligase activity
Uniprot Accessions :
P61088
Gene :
UBE2N
GeneID URL :
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=7334
EntityFormats :
Purified
UNSPSC :
41116161
Concentration :
IgG concentration 1.0 mg/ml
Product Form :
Purified IgG - liquid
PrimarySecondary :
Primary
company information

Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.
questions and comments